Abstract: Methylxanthines, such as theophylline, have been used to treat cardiorespiratory disorders, whereas caffeine is the most widely consumed psychoactive agent in various soft drinks. Because of the worldwide use of these drugs and the recently synthesized xanthine derivatives, an intensive research on the cardiac actions of these substances is under progress. This review focuses on the molecular mechanisms involved in the actions of xanthine derivatives with special reference to their adenosine receptor antagonistic properties. The main basic and human studies on the action of xanthines on impulse initiation and conduction, as well as the electrophysiological and mechanical activity of the working myocardium will be overviewed. The potential beneficial and harmful actions of the methylxanthines will be discussed in light of the recent experimental and clinical findings. The pharmacological features and clinical observations with adenosine receptor subtype-specific xanthine antagonists are also the subject of this paper. Based on the adenosine receptor-antagonistic activity of these compounds, it can be raised that xanthine derivatives might inhibit the cardioprotective action of endogenous adenosine on various subtypes (A1, A2A, A2B and A3) of adenosine receptors. Adenosine is an important endogenous substance with crucial role in the regulation of cardiac function under physiological and pathological conditions (preconditioning, postconditioning, ischemia/reperfusion injury). Recent clinical studies show that acute administration of caffeine or theophylline can inhibit various types of preconditioning in human subjects. There are no human studies, however, for the cardiovascular actions of long-term administration of these drugs. Upregulation of adenosine receptors and increased effectiveness of adenosine receptor-related cardiovascular functions have been observed after long-lasting treatment with methylxanthines. In addition, there are data indicating that blood adenosine level increases after long-term caffeine administration. Since the salutary actions (and also the adverse reactions) of a number of xanthine derivatives are repeatedly shown, the main goal is the development of novel structures that mimic the actions of the conventional methylxanthines as lead compounds, but their adenosine receptor subtype-specificity is higher, their water solubility is optimal, and the unwanted reactions are minimized.
INTRODUCTION
The commonly used methylxanthines theophylline, caffeine and theobromine are naturally occurring compounds in various plants. These substances are components of most widely consumed beverages, coffee, tea and cocoa. Theophylline and its salts (aminophylline, choline theophyllinate) or derivatives (enprophylline, doxofylline, bamiphylline) -depicted in Fig. (1) -are used in the therapy of bronchial asthma and chronic obstructive pulmonary disease (COPD), whereas pentoxyphylline in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, as well as in diabetic neuropathy [1] . Occasionally theophylline is applied to prevent sleep apnea in adults. Caffeine is an analeptic and central nervous system stimulant drug being generally used for enhancement of arousal and vigilance, suppression of fatigue, as well as to shorten reaction time of the motor system. In addition, caffeine has long been used as an adjuvant in combinations to potentiate the pharmacological actions of various analgesics such as acetaminophen and acetylsalicylic acid [2, 3] .
Methylxanthines, like theophylline or caffeine, are also widely used in cardiology, since these drugs are appropriate medicaments for treatment of various bradyarrhythmias and disturbances of atrioventricular conduction. In some selected cases, theophylline may be used as classical "ino-dilator" and diuretic [4] .
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phosphodiesterase enzyme and induce mobilization of calcium from the sarcoplasmic reticulum. It is now becoming clearer that the mainstream of the site of actions of methylxanthines are the adenosine receptors, at least, in the therapeutically relevant concentrations of 20-50 M [4, 5] . Accordingly, in this paper we discuss the cardiac actions of methylxanthines when applied in both therapeutic and toxic concentrations. We emphasize the cardiac electrophysiological effects of xanthines with special reference to antagonistic actions on adenosine receptors.
MECHANISM OF ACTION OF METHYLXANTHINES AND OTHER XANTHINE DERIVATIVES: BASIC STUDIES

Basic Studies on Acute Actions of Methylxanthines and other Xanthine Derivatives
Caffeine in millimolar concentrations has been shown to induce various electrophysiological effects on pacemaker fibers and working myocardium. These effects display wide interspecies dependence. Thus, in rabbit sinoatrial nodal cells, caffeine (1 to10 mM) induced a concentration-dependent, atropine-resistant decrease in sinoatrial pacemaker activity. Caffeine increased the slow inward current, reduced the delayed rectifying outward current, and elevated the cytoplasmic Ca 2+ concentration. Some of the preparations displayed arrhythmias resulting from the caffeine-induced calcium overload. The observed sinus bradycardia can also be related to this latter mechanism [6] . In canine cardiac Purkinje fibers, caffeine (0.5 to 3 mM) induced an oscillatory potential, which could be modulated by altering intracellular calcium concentration. This oscillatory potential explained the arrhythmias observed in Purkinje fibers [7] . In human atrial fibers theophylline (0.1 to 1 mM) was shown to increase the rate of phase 4 depolarization and the amplitude of the oscillatory potential during diastole and induced the development of spontaneous slow action potentials. These findings represent the major electrophysiological basis helping to understand the theophylline-induced atrial ectopic activity [8] . In working myocardium caffeine stimulated the L-type Ca 2+ -current (I Ca ) [9, 10] . This effect can be ascribed to the ability of caffeine to activate the ryanodine channels in the sarcoplasmic reticulum. Caffeine is known to increase the calcium-induced calcium release, amplifying thus the slow inward current [11] . In contrast, there are studies indicating an inhibitory action of caffeine on I Ca [12, 13] . In rat ventricular myocytes, Varro et al. [14] found that high concentration (20 mM) of caffeine reduced the amplitude of the inward rectifier potassium and inward calcium currents. Zhang et al. [15] described a caffeineactivated large-conductance plasma membrane cation channel in cardiac myocytes. It was suggested that this can be an additional mechanism by which caffeine and theophylline may contribute to generation of cardiac arrhythmias.
It is important to take into account that these changes occur in a concentration range of 1 to 20 mM of methylxanthines. This range is well above those xanthine concentrations (20-50 M) which can be reached during therapeutic interventions or by consuming caffeine-containing soft drinks. The cardiac actions of methylxanthines could not be explained by their phosphodiesterase inhibiting action or by mobilization of intracellular calcium, since these effects of methylxanthines are very slight at concentrations below 100 M. On the other hand, methylxanthines have been shown to antagonize adenosine receptors effectively within their therapeutic concentration range [16] . Therefore, it is conceivable that cardiac activity of methylxanthines can be related to their antagonistic actions directed to endogenous adenosinergic signalization [17] .
Adenosine is an endogenous, crucial signaling purine nucleoside that plays prominent role in regulation of cardiovascular function, having also an important role in pathogenesis of various cardiovascular diseases. Adenosine is much implicated in the control of local blood flow of various organs [18] , regulation of cardiac pacemaker activity, AV conduction, myocardial contractility, and cardioprotection [19] [20] [21] [22] [23] . Adenosine acts through G protein-coupled receptors on the target cells. Until recently, four subtypes of adenosine, namely A 1 , A 2A , A 2B and A 3 , have been identified structurally, functionally and pharmacologically. These adenosine receptors were characterized on the basis of their specific pharmacological profile (rank order of potency of agonists and antagonists), G protein coupling, and signaling mechanism involved in the subtypespecific adenosine receptor activation. All subtypes of adenosine receptors are available in the heart [24] . A 1 adenosine receptors are negatively coupled to adenylyl cyclase, and are responsible for the reduction of sinoatrial rate, AV-conduction, atrial contractile force, attenuation of the positive inotropic effect of catecholamines, as well as for the protection against myocardial ischemia/reperfusion injury. A 2A receptors are positively coupled to adenylyl cyclase. They are expressed in rat ventricular myocardium and are known to counteract some A 1 adenosine receptor-mediated anti-adrenergic actions [25] . A 2B adenosine receptors couple positively to adenylyl cyclase, and mitogen-activated protein kinase. These receptors were suggested to modulate cellular hypertrophy [26] . A 3 receptors, like A 1 adenosine receptors, are negatively linked to adenylyl cyclase. Their activation could inhibit the -adrenergic receptor activationinduced enhancement of cAMP, as well as provides tolerance against hypoxic injury [27] . To understand all cardiac actions of methylxanthines, it is necessary to shortly survey the main effects of adenosine on the cardiac pacemakers, conduction systems and the working myocardium.
Regarding the action of adenosine on impulse initiation and conduction, the first described action of adenosine was slowing of the heart rate [28] . In spontaneously beating isolated right atrial myocardium, His bundles, and Purkinje fibers of guinea pigs, adenosine showed a characteristic suppressive effect on the spontaneous firing rate in these specific pacemaker cells [29] [30] [31] [32] [33] [34] [35] . A 1 adenosine receptor activation enhanced the inward rectifier potassium current (I K-Ado ), and consequently hyperpolarized the cell membrane resulting in reduction of the slope of phase 4 depolarization [36] [37] [38] . Adenosine has also been reported to inhibit the pacemaker current (I f ) in sinoatrial and AV nodal cells [39] [40] [41] . In human, Honey and his colleagues were the first to describe in 1930 [42] that adenosine induced sinus bradycardia. Endogenously released adenosine might have a role in hypoxia-or ischemia-induced bradycardia, since the adenosine receptor antagonist aminopylline antagonized the hypoxia-induced suppression of sinoatrial pacemaker activity in spontaneously beating guinea pig right atrial preparations. As for humans, Watt has proposed that adenosine might be involved in bradyarrhythmias related to sick sinus syndrome [43, 44] .
Drury and Szent-Györgyi were the first to identify adenosineinduced heart block [28] . Later, Stafford observed that adenosine caused a concentration-dependent atrioventricular conduction block in guinea pig hearts [45] . Adenosine is also capable to induce an impaired or blocked of atrioventricular nodal conduction in humans [42, 46] . This is generally a short-lived, not too serious, adverse reaction, but prolonged complete heart block requiring intubation and temporary pacing has also been reported [47] . A 1 adenosine receptors are abundantly expressed in the AV junction. Adenosine acts on the proximal part of atrioventricular junction (atrio-nodal region and nodal region), whereas no effect was observed on the nodal-His bundle [48] . In the negative dromotropic effect of adenosine, activation of the inward rectifier potassium current and the concomitant hyperpolarization of the cell membrane may have a crucial role. In addition, inhibition of L-type calcium channels has also been a suggested as underlying mechanism [39] .
Adenosine is thought to be exerted a strong depressant effect on atrial myocardial contractility. The negative inotropic effect of adenosine has been described in electrically driven rat [49] , guinea pig, and human atrial preparations [50] [51] [52] [53] . The negative inotropic effect in atrial myocardium is related to the marked shortening of action potentials [22, 49, 51, 54, 55] . Based on microelectrode recordings and 42 K flux measurements, Jochem and Nawrath were the first to report that adenosine activated a potassium conductance [55] . Belardinelli and Isenberg, using voltage-clamp technique in single atrial myocytes, showed that the adenosine-activated conductance was an inwardly rectifying potassium current [36] . It was also revealed that the adenosine-and acetylcholine-activated conductances are identical, and these channels are associated with the receptors via a pertussis toxin-sensitive G-protein. Schrader et al. reported that adenosine reduced the rate of rise and amplitude of the slow action potential in guinea pig atrial preparations [56] . Now it is clear that the mechanism of the depressant effects of adenosine on the atrial myocardium is related to activation of the inwardlyrectifying potassium current (I K-Ado ) and a blockade of the slow inward current mediated by L-type Ca 2+ channels [57] .
Adenosine exerts quite different actions on contractility in atrial and ventricular myocardium. Under baseline conditions, adenosine had no negative inotropic action in ventricles -it displayed rather a moderate positive inotropic effect [58] [59] [60] [61] [62] [63] [64] . Importantly, adenosine had no effect on action potential duration or baseline L-type calcium current [65] . In contrast, in ventricular myocardium when adenylate cyclase was previously activated using various compounds, including isoprenaline, histamine and dopamine, adenosine displayed a negative inotropic action [58, 63, 64, [66] [67] [68] . Under these conditions adenosine or adenosine analogues attenuated all catecholamine-stimulated outward and inward currents. With the exception of rat and ferret, no adenosine-activated potassium current can be demonstrated in ventricular myocardium [39] . In addition, the anti-adrenergic action of adenosine is due to an inhibition of adenylate cyclase activity with the concomitant reduction of cAMP content [10, 28, 29, 45] . On the other hand, adenosine has been shown to exert significant anti-adrenergic effect on myocardial preparations [64, 66] . Accordingly, there is a concept that adenosine acts as a negative feedback modulator of -adrenoceptormediated responses in the heart [64, 66] . Although ventricular myocardium contains primarily A 1 adenosine receptors, there are studies showing that A 2A and A 3 adenosine receptors are also expressed in ventricular myocytes [24] .
Accordingly, methylxanthines are capable to antagonize the actions of both exogenous and endogenous adenosine. The competitive antagonism between methylxanthines and exogenous adenosine in various cardiac functions has long been established [69] [70] [71] .
A great mass of experimental evidence is available for establishing the ability of methylxanthines to antagonize the effects of endogenous adenosine accumulated in certain conditions, like hypoxia, ischemia, or increased metabolic activity. Regarding atrioventricular conduction, Belardinelli et al. [72] demonstrated that adenosine, like hypoxia, exerted a concentration-dependent prolongation of AV conduction in perfused guinea pig heart. Actions on conduction delay induced by both hypoxia and adenosine could be antagonized by aminophylline, an adenosine receptor antagonist. Belardinelli et al. [72] finally suggested that endogenously released adenosine might play an important role in AV conduction disturbances also in case of acute hypoxia. Similar conclusions have been drawn in other studies [73, 74] .
In our previously reported experiments [75] , sinoatrial pacemaker activity of spontaneously beating guinea pig left atria was recorded using extracellular electrodes. During moderate hypoxia, the sinoatrial firing rate gradually decreased. This bradycardia was effectively antagonized by aminophylline, while enhanced in the presence of the adenosine deaminase inhibitor coformycin and the membrane purine transport uptake blocker dipyridamole, indicating the crucial role of the accumulated adenosine in the sinus bradycardia occurring under hypoxic conditions.
A similar experiment is presented in Fig. (2) , using another xanthine-type adenosine receptor antagonist, 8-p-(sulphophenyl)theophylline. This xanthine prevented the moderate hypoxia-induced decrease in sinoatrial pacemaker activity practically completely. As this compound acts on only at extracellular sites, therefore an additional inhibitory action of enzyme phosphodiesterase can be excluded. In electrically stimulated guinea pig atria, under normoxic conditions, theophylline induced a significant increase of contractile force within a concentration range of 0.1-1 mM, which is higher than usual adenosine receptor-antagonist concentrations [76] . According to Collis et al. [77] , the positive inotropic actions of theophylline and enprophylline were not due to adenosine receptor blockade, but rather to inhibition of phosphodiesterase. According to experiments of Bellemann and Scholz [78] , the positive inotropic actions of high concentration (0.6 mM) of theophylline can be associated with an increase of sarcolemmal calcium influx and an action on intracellular calcium binding or storage sites. In electrically driven left atrial preparations of guinea pigs, adenosine reduced the contractile force and shortened the duration of intracellularly re- minutes during hypoxia % of pre-hypoxia control corded action potentials. The similarity between the adenosine-and the hypoxia-induced alterations of myocardial electrical and mechanical activities is striking, since both the adenosine-and hypoxia-induced changes could readily be prevented by aminophylline. Extreme changes in action potential morphology due to longlasting hypoxia could also be reversed by aminophylline. On the basis of these results it is assumed that the increased tissue level of endogenous adenosine in acute myocardial hypoxia might contribute to functional impairment of atrial myocardium [21] . In normoxic conditions, methylxanthines, in therapeutically applied concentrations, do not alter or minimally affect the functional activity of myocardium and pacemaker tissues. It can be supposed that stimulatory actions of methylxanthines applied in therapeutic concentrations occur only under pathological conditions (e.g. hypoxia, ischemia), when endogenous tissue adenosine levels are substantially elevated.
Basic Studies on Chronic Actions of Xanthine Derivatives
In contrast to the extensive studies performed on the regulation of CNS adenosine receptors, there is only limited information available on the effect of chronic methylxanthine treatment on the cardiovascular action of adenosine. In the study by Wu et al. [79] the action of a 2-week theophylline treatment on myocardial A 1 adenosine receptors was investigated. Cardiac adenosine receptors were upregulated by chronic exposure to theophylline and this upregulation was accompanied by an increased sensitivity of ventricular myocytes to the electrophysiological and biochemical effects of adenosine receptor agonists. Similarly, chronic (2 weeks) theophylline treatment resulted in upregulation of atrial and ventricular A 1 adenosine receptors in rats [80] . It must be noted, however, that only the indirect, antiadrenergic, negative inotropic and chronotropic effects of adenosine receptor agonist on atrial muscle were sensitized, but the direct cardioinhibitory actions were not altered. Chronic caffeine consumption (3 weeks) potentiated the A 2 adenosine receptor-related hypotensive action of adenosine in rats [81] . According to Varani et al. [82] , repeated caffeine administration upregulated human platelet adenosine A 2A receptors, which is accompanied with an increased antiaggregatory action of the A 2A adenosine receptor agonist 2-hexenyl-5'-N-ethylcarboxamidoadenosine. Similar results were obtained also in rat platelets [83] . Interestingly, in an experiment with repeated (23 days) administration of a selective A 1 adenosine receptor antagonist KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine) Kusaka and Karasawa [84] failed to observe any alteration in the A 1 adenosine-receptorrelated bradycardic action of 5'-N-ethylcarboxamidoadenosine (NECA).
In our experiments, the actions of long-term oral caffeine treatment were studied on the electrical and mechanical activity of A 1 adenosine receptor selective N 6 -cyclopentyladenosine (CPA) on guinea pig atrial myocardium, as well as on the antagonistic action of methylxanthines on the CPA-induced decrease of mechanical activity in atrial myocardium. Slow action potentials were generated in potassium-depolarized (25 mM) guinea pig atrial muscles treated by 1 M isoproterenol. CPA decreased the rate of rise and the duration of slow action potentials (Fig. 3, Table 1 ) in a concentration-dependent manner. A very strong sensitization in the CPAinduced electrophysiological changes was observed after a 2 week caffeine treatment.
On the basis of these experiments it can be suggested that after long-lasting caffeine treatment a strong sensitization develops in the CPA-induced depression of slow Ca 2+ influx and outward K + outflow. It is thought that under these conditions V max represents the slow inward Ca 2+ current, whereas duration of slow action potential is related to the outward potassium current [56] . In these experiments, guinea pigs were fed with caffeine for 10 weeks, their average serum caffeine concentration was 42.3 ± 3.6 M. In electrically driven left atrial preparations, sensitization to CPA-induced decrease of mechanical activity developed. Its maximum was observed at week 2 of caffeine treatment, then the potency ratio moderately diminished ( Table 1) . From week 2, the E max values were also elevated in atrial muscles of caffeine-treated groups. It is noteworthy, that at week 10 of caffeine treatment a moderate tolerance developed in the adenosine-antagonistic action of various methylxanthines (e.g. theophylline, caffeine, and DPCPX), i.e. their antiadenosine pA 2 values were reduced. From these studies, an upregulation of A 1 adenosine receptors due to chronic caffeine treatment, resulting in alterations in electrical and mechanical parameters of atrial myocardium, can be concluded.
HUMAN STUDIES
There are a number of early reports, indicating that the resting sinus frequency or the increase during exercise fails to alter significantly after therapeutic doses of caffeine [85] . Interestingly, in various pathological states or in healthy volunteers at various submaximal and maximal exercise intensities, when tissue concentration of endogenous adenosine elevates, methylxanthines exert noticeable effects on the sinoatrial pacemaker. It is suggested by Watt [43] that sick sinus syndrome is an adenosine-mediated disease. In this syndrome, oral theophylline proved to be efficacious in increasing sinus rate at rest and during exercise, and also to reduce cardiac pauses [86, 87] . In a randomized, controlled trial (The THEOPACE   Fig. (3) . CPA-induced, concentration-dependent depression of maximum velocity of depolarization (Vmax) and shortening of the duration of slow action potentials generated in guinea pig atrial trabeculae depolarized by 25 mM potassium and treated with 1 M isoproterenol. The preparations were stimulated at a frequency of 0.5 Hz, transmembrane potentials were recorded using conventional sharp microelectrodes. 
SOLVENT-TREATED CAFFEINE-TREATED
Study) it was, however, shown that oral theophylline reduced only the minor symptomes of sick sinus syndrome, while was not effective in patients suffering from severe forms of the disorder [88] . Human electrophysiological studies are also available to demonstrate that oral theophylline suppressed the symptoms in sick sinus syndrome [89, 90] . Benditt et al. [90] reported that theophylline treatment was useful in young patients with recurrent symptomatic bradyarrhythmias. Furthermore, it was suggested that theophylline might be a reasonable alternative strategy in the treatment of chronic symptomatic bradycardia in the elderly [91, 92] .
Sinus node dysfunction, primarily sinus bradycardia, is frequently associated with heart transplantation [93] . Bertolet and his coworkers [94] observed that use of theophylline for posttransplantation bradyarrhythmias was efficient in increasing the heart rate and reduced the need for implantation of a permanent pacemaker. Reversibility of prolonged chronotropic dysfunction by theophylline and aminophylline following orthotopic cardiac transplantation was also reported by a number of investigators [95] [96] [97] . Oral or intravenous theophylline proved to be effective in not only sinus node disturbances, but also in abnormal impulse conduction. Thus, Alboni et al. [97] described that oral theophylline represents a valid therapy in most patients with atrial fibrillation associated with a slow ventricular response. Intravenous theophylline proved to be a useful method in the management of bradycardia secondary to AV block and offers a pharmacological alternative to patients where other pharmacological strategies or cardiac pacemaker implantation may be contraindicated [98] . An interesting observation was reported by Bertolet et al. [99] , who demonstrated the effectiveness of theophylline in atrial fibrillation due to adenosine accumulation in acute myocardial infarction. After application of theophylline, a rapid (< 5 min) and long-term conversion of atrial fibrillation to sinus rhythm was observed. These findings highlighted the role of endogenous adenosine in development of atrial fibrillation and the possibility of an adenosine antagonist-based therapy. As theophylline is not a specific adenosine receptor antagonist, it is hopeful that A 1 adenosine receptor selective antagonists (e.g. synthetic methylxanthines) can be more efficient drugs to terminate this type of atrial fibrillation [74] . It is noteworthy that after caffeine consumption different changes in sinus rhythm were observed in healthy humans exposed to various submaximal and maximal exercise intensities. Thus, some investigators reported that caffeine increases the heart rate under these circumstances [100] [101] [102] [103] . Recently, McClaran and Wetter [104] reported that in non-habitual caffeine users, low doses of caffeine decreased the heart rate during submaximal exercise, but not at near maximal and maximal exercise. It is tempting to suppose that because of the imbalance between oxygen requirement and consumption in maximal physical exercise, endogenous adenosine release can substantially be increased. In this case caffeine might counterbalance the endogenous adenosine-related suppression of sinoatrial pacemaker activity.
There are conflicting reports available on the possible arrhythmogenic action of caffeine or theophylline. According to a metaanalysis, moderate consumption of caffeine does not increase the frequency or severity of cardiac arrhythmias in healthy persons, in patients with ischemic heart disease, or in ones having pre-existing serious ventricular ectopy. There is an increase, however, in the frequency of ventricular extrasystoles in heavy coffee consumers drinking 9 or more cups daily [105] . It was recently found that moderate tea intake can be associated with a lower prevalence, while higher coffee consumption with a slightly higher prevalence of ventricular arrhythmias in patients hospitalized with acute myocardial infarction [106] . According to the Danish Diet, Cancer, and Health Study [107] , in which 47 949 subjects were participated, consumption of caffeine was not associated with an elevated risk of Table 1 . atrial fibrillation or flutter. Similarly, at modest dose of caffeine, no action on the incidence of ventricular arrhythmia could be observed in patients with ventricular tachycardia or fibrillation [108, 109] .
Effects of Long-Term Caffeine Treatment on the CPA-Induced Alterations in the Mechanical and Electrical Activity of Guinea Pig
Regarding the effects of methylxanthines on the working myocardium, the picture is quite complex. Conrad and Prosnitz [110] studied the cardiovascular actions of aminophylline-infusion in healthy male volunteers and found that aminophylline exerted a mild positive inotropic effect, but this action could be prevented by pretreatment with the -adrenergic receptor antagonist metoprolol or propranolol. The hemodynamic action of intravenously applied aminophylline was also studied in healthy human subjects and no significant improvement was found on cardiac performance during tread-mill exercise after using of the compound [111] . These findings are in good agreement with the further study of Conradson using theophylline and enprophylline [112] . According to the hemodynamic studies of Parker et al. [113] , aminophylline was effective to increase cardiac output in patients suffering from heart failure, but no change was observed in patients with cor pulmonale [114] or chronic obstructive pulmonary disease [115] .
Theophylline and aminophylline were extensively used over the last 70 years to increase inotropy in patients suffering from heart failure [113, 116] , and to treat patients with bronchial asthma [117] . However, because of the narrow therapeutic ratio and due to its cardiac, gastroenteric and CNS side effects, theophylline has lost popularity in the last decades. According to current AHA and ESC guidelines, the two primary pharmacological approaches in symptomatic heart failure are ACE inhibitors/ARBs and diuretics. Theophylline exerts a slight positive inotropic action combined with a good vasodilator activity, therefore, it can be an ideal drug for combined inotropic and vasodilator treatment of heart failure. In addition, theophylline and its derivatives have also moderate diuretic activity based on adenosine receptor antagonism [118] , decreasing thus the circulating blood volume and preload of the heart. Endogenous adenosine was also shown to play an important role in pathogenesis of heart failure. Plasma adenosine levels are increased in patients with heart failure in parallel with the severity of the disease [119] . In the nephron, A 1 and A 2 adenosine receptors are widely distributed and they have significant functional role. Adenosine can influence the glomerular filtration rate, renal hemodynamics, and the tubuloglomerular feedback. This purine nucleoside reduces glomerular filtration by inducing selective vasoactive actions on the postglomerular and preglomerular vessels. Adenosine constricts the preglomerular vessels by activation of A 1 adenosine receptors, whereas exerts a vasodilator action on the postglomerular arterioles by stimulation of A 2 receptors [120] . Activation of A 1 receptors decreases renal perfusion pressure, glomerular filtration, and tubular sodium reabsorption [121] . It is supposed that adenosine may play a role in the kidney-mediated fluid retention in heart failure [122] . In this case, use of selective A 1 adenosine receptor antagonists might provide therapeutic benefits in the setting of congestive heart failure. At present, one of the primary approaches of treatment of heart failure is diuretic therapy. On the basis of clinical experiences, however, it became clear that the generally applied diuretics (e.g. furosemide) may reduce glomerular filtration rate in patients suffering from heart failure [120, 123] . In contrast, selective blockade of A 1 adenosine receptors by CVT-124 was shown to reduce afferent arteriole pressure, increase the urinary flow and sodium excretion [124, 125] . It is logical to assume that treatment with selective A 1 adenosine antagonists can be more effective than the conventional diuretic therapy.
The chemical structures of some novel A 1 adenosine receptor selective compounds are presented in Fig. (4) . The newest drug in this category is rolofylline (KW-3902). In a randomized, placebocontrolled, dose-finding study (PROTECT Pilot Study), it was observed that A 1 adenosine receptor blockade with rolofylline could prevent renal impairment in patients with acute heart failure and positively affected the acute symptoms as well as the 60 days outcome [126] . The large clinical trial, PROTECT, began in May 2007 and was completed in January 2009. 2033 patients from 173 sites of 19 countries were recruited in this study. The results were disappointing as in the larger trial the benefits observed in the PROTECT Pilot Study could not be replicated. Rolofylline showed no difference from placebo regarding the primary end-points in patients with acute heart failure. In the study, there was a trend toward a lower incidence of serious adverse cardiac side reactions, but the incidence of neurological events (seizures and strokes) were higher. As a consequence, the drug has been dropped from development [127] [128] [129] . The clinical trial with another A 1 adenosine receptor-selective blocker, naxifylline was also discontinued [130] . At present, it is not clear whether the basic principle is a pitfall or there might be problems with the physicochemical properties of the investigated drugs?
The resolution of this issue should be very important for the future trends of drug development. Currently there is only one A 1 receptor-selective xanthine derivative, toponafylline under clinical trial for treatment of heart failure [130] .
CURRENT PROBLEMS AND FUTURE PERSPECTIVES
Independently of the above mentioned facts, it appears that theophylline receives a renewed attention as according to a number of studies. This drug -applied in relatively low doses -was able to exert significant anti-inflammatory action in patients with bronchial asthma and chronic obstructive pulmonary disease [117, [131] [132] [133] [134] [135] . On the basis of this recognition, a new era of use of methylxanthines may start, the significance of which could affect not only the treatment conceptions of cardiorespiratory diseases, but also the synthesis of new and more effective methylxanthines. When considering the ongoing and future use of methylxanthines, we should take into account a number of issues. According to the title of this work, we should wage the benefits and risks of xanthine treatment.
The main facts are as follows. (1) caffeine is the most widely consumed and relatively safe psychoactive agent all over the world. (2) Although treatment guidelines have regulated theophylline to third-line treatment of bronchial asthma and chronic obstructive pulmonary disease [136, 137] , the rate of theophylline users among asthmatic and COPD patients is relatively high [138] . (3) The antiinflammatory action of theophylline, observed in low dose, will likely facilitate the worldwide use of theophylline again [117, 135] . (4) There is an intense, lengthy interdisciplinary endeavor for developing new, more selective and more effective xanthine derivatives. Although, according to large studies the moderate consumption of caffeine-containing beverages does not associate with an increased cardiovascular mortality and morbidity, there are some concerns that the use of methylxanthines should be taken into account in point of view of possible cardiovascular consequences. Thus, it was emerged that methylxanthines are able to eliminate the preconditioning actions of endogenous adenosine [139] . As adenosine receptors are highly implicated in ischemia/reperfusion process, the same suggestion might also be conceivable for treatment with various xanthines having adenosine receptor-antagonist properties. As for the possible implication of theophylline and xanthine structures, we will focus exclusively on four interesting aspects of cardiac activity: possible implications for (1) preconditioning, (2) postconditioning, (3) ischemia/reperfusion injuries, and (4) epigenetic processes in the heart.
Possible Implications for Preconditioning
It is widely believed that adenosine is a highly effective endogenous cardioprotective agent, which plays important role in ischemic preconditioning. It has been observed that a short period of ischemia increases the tolerance against a subsequent sustained ischemia [140, 141] . This might be the basis of the experience that the infarct size is smaller in patients who had several anginal attacks before acute myocardial infarction [140] . Preconditioning may occur in two phases: an early phase, called also early preconditioning, and a delayed phase often mentioned as a second window of protection. The delayed phase of ischemic preconditioning is supposed to implicate synthesis of cytoprotective proteins [142] . There is good evidence that A 1 and A 3 adenosine receptors have crucial role in adenosine-mediated preconditioning in both experimental animals [143] [144] [145] [146] [147] [148] [149] and human subjects [150, 151] . In preconditiong, the role of adenosine is supported by strong pharmacological evidence, indicating that various xanthine-type adenosine receptor blockers, like 8-p-(sulphophenyl)theophylline, 8-(4-carboxyethenylphenyl)-1,3-dipropylxanthine (BW A1433), and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) effectively eliminated preconditioning [147, 152] . Recently, Riksen et al. [139] and Meijer et al. [153] have shown that acute caffeine administration prevented protection in two different human models of ischemic preconditioning. Schaefer et al. [154] , as well as Claeys and his associates [155] observed that blockade of adenosine receptors with aminophylline limited ischemic preconditiong in human beings. Tomai and his coworkers [150] described that adenosine receptor blockade by bamiphylline inhibited the ischemic preconditioning during coronary angioplasty. The same group [156] has also demonstrated that bamiphylline improved exercise-induced myocardial ischemia, increased the ischemic threshold, prolonged exercise duration, delayed the onset of anginal pain, and reduced the ST segment depression -possibly via selective blockade of A 1 adenosine receptors.
Possible Implications for Postconditioning
Myocardial ischemia is always followed by reperfusion associated myocardial necrosis and apoptosis. This reperfusion injury can be diminished by postconditioning, which was first described by Zhao et al. [157] . Postconditioning includes a brief ischemic episode immediately at the onset of reperfusion after a prolonged ischemic episode. This intervention was shown to reduce the size of the infarct area [157] [158] [159] . Although, the literature data are conflicting, it seems likely that A 2A and A 2B adenosine receptors may play critical role in postconditioning [160] [161] [162] , however, involvement of A 1 and A 3 adenosine receptors have also been emerged [163] .
Possible Implications for Ischemia/Reperfusion Injury
Adenosine is known to exert a protective effect against ischemic injury. In the adenosinergic cardioprotection, practically, all subtypes of adenosine receptors contribute. A 1 adenosine receptor-induced cardioprotection operates when the receptors are activated prior to and during ischemia. During reperfusion, A 1 adenosine receptor activation is not effective [163] [164] [165] [166] [167] . Although, in human, the expression of A 3 adenosine receptors is relatively poor, there are pharmacological proofs to support the protective role of A 3 receptor activation both in the pre-and post-ischemic period, as well as during ischemia [160, [168] [169] [170] . In contrast to A 1 and A 3 adenosine receptors, A 2A and A 2B adenosine receptors do not play a significant role in the pre-ischemic and ischemic phase, but are highly effective during reperfusion [163, 164, [170] [171] [172] [173] . Several experimental studies provide evidence that blockade of any of the known adenosine receptor subtypes could somehow diminish the cardioprotective action of adenosine [163, 174] .
Possible Implications for Epigenetic Mechanisms
The term "epigenetics" describes all meiotically and mitotically heritable alterations in gene expression that are not coded in the DNA sequence itself [175] . Epigenetic mechanisms involves DNA methylation, RNA-associated silencing and histone modification. Histone modifications as epigenetic modifiers are post-translational modifications of histones, including acetylation and methylation of conserved lysine residues. Histone deacetylases (HDACs) regulate cellular signaling and gene expression. Until recently, distinct genes encoding 18 mammalian HDACs (grouped into Class I, II and III) have been identified [176] . Histone deacetylase 2 (HDAC2) is a critical factor for embryonic development and cytokine signaling relevant for immune responses. Pathologic activity of this enzyme can lead to various cardiac disturbances such as myocardial hypertrophy or heart failure [177] . Thus, inhibitors of HDAC2 enzyme are considered as important cardiac drugs, to be applied e.g. for prevention of myocardial hypertrophy [176, 178, 179] . It is noticeable that Class IIa HDACs (HDAC 4, 5 and 9) repress myocardial hypertrophy and Class I and Class IIa enzymes have opposing roles in regulation of cardiac myocyte growth and heart diseases [180] . The roles of various HDACs are quite complex and they might also be involved in pathogenesis of cardiac arrhythmias and acute coronary syndromes [179] .
This epigenetic mechanism might be significant in patients suffering from bronchial asthma and COPD. It was repeatedly de-scribed that low concentrations of theophylline activated HDAC and suppressed the activation of inflammatory genes [134, 181] . This action could be observed at low (1 to 10 M) theophylline concentrations, whereas is lost at higher theophylline levels (100 M). Theophylline activates different subtypes of HDACs via an intracellular site of action, but it appears that it has a relatively more selective action on Class I than on Class II HDACs [182] . To our best knowledge, there are no reports on the action of theophylline and other xanthine derivatives on the cardiac HDACs, but it should be strictly considered whether these low theophylline levels might affect also the physiological or pathological cardiac functions? At present, we do not know whether theophylline can be regarded as a friend or a foe on the heart in this regard. Because the actions of various HDACs are very complex, the outcome of activation of these enzymes can be either beneficial or harmful. Extensive clinical studies are necessary to reveal the significance of this issue.
CONCLUSIONS
The main goal of this paper was to review the current state of the medical use and perspectives of xanthine structures, such as theophylline, caffeine and some of the novel adenosine subtypespecific xanthine derivatives. It can be stated that the conventional methylxanthine theophylline is still frequently prescribed worldwide, but the frequency of adverse reactions and the relatively low efficacy of this drug have led to reduced use in the pulmonological practice. The recent recognition of the specific anti-inflammatory action of low theophylline doses as a HDAC activator will possibly significantly accelerate the worldwide application of theophylline. It is tempting to speculate that the anti-inflammatory property of theophylline or theophylline-derivatives could be used in not only in bronchial asthma and COPD, but also in ischemia/reperfusion injuries, such as heart transplantations or acute myocardial infarction. In the reperfusion phase of these cardiovascular events the crucial role of the inflammatory processes are widely accepted [183] [184] [185] [186] . It has been shown that pretreatment with aminophylline before coronary artery bypass grafting or heart transplantation improved the mechanical and biochemical functions of the heart in human subjects [187, 188] . Regarding caffeine, this drug possibly remains the most widely consumed psychoactive substance in the future. There are intensive endeavors to synthesize new adenosine subtype-selective xanthine derivatives. Two A 1 subtype selective, xanthine-type adenosine receptor antagonists were under clinical trials (rolofylline, naxifylline), but these studies were discontinued. At present, only toponafylline (BG-9928) is in a phase IIb clinical trial for treating heart failure (Fig. 4) . Xanthine-type A 2A antagonists were also under clinical trial in Parkinson disease, e.g. istradefylline (KW-6002) and ST-1535. ST-1535 is under phase I trial, whereas the study with istradefylline was discontinued [130] . Two xanthine-type A 2B adenosine receptor antagonists are under clinical development for bronchial asthma (ATL 844 and GS 6201) [130] .
It is surprising that relatively few subtype-selective xanthinetype antagonists were chosen for human studies and approximately half of the trials were discontinued because of ineffectiveness or adverse reactions. It appears that we should consider primarily the cardiac actions of caffeine, theophylline and their derivatives. It would be a useful option to develop compounds, like 8-p-(sulphophenyl)theophylline (8-SPT; Fig. 5), 8-(4'-carboxymethyloxyphenyl)-1,3 -dipropylxanthine or 8-(4'-carboxymethyloxyphenyl)-1,3-dipropylxanthine-2-aminoethylamide as theophylline derivatives, which are not able or very poorly able to penetrate the blood brain barrier [189] . With the use of these types of compounds, the central nervous system effects, like seizures, could effectively be avoided.
The actual concern is that how xanthine structures could influence pre-and postconditioning, as well as ischemic-reperfusion injuries. As highlighted above, there are clinical experiences indicating that methylxanthines can inhibit preconditioning and the question emerged, whether these adenosine receptor antagonists can blunt the cardioprotective activity of endogenous adenosines. First, these clinical observations refer exclusively to acute administration of methylxanthines. Until recently, there are no chronic human trials. Second, there are experimental findings that adenosine receptors are upregulated and the adenosine-induced physiological responses are concomitantly increased under chronic exposure to methylxanthines [79] [80] [81] [82] [83] . In this paper, we clearly demonstrated that -at least in guinea pigs -the long-term administration of oral caffeine administration may strongly enhance the A 1 adenosine receptor-induced electrical and mechanical responses in electrically driven left atrial myocardium. These findings strongly suggest that under chronic administration of caffeine or theophylline, adenosine receptors participating in preconditioning or ischemia-reperfusion processes are upregulated. Therefore, it can be predicted that longlasting exposures to these methylxanthines do not worsen, but rather improve the effectiveness of these endogenous cardioprotective mechanisms. In addition, it should be taken into account that caffeine is capable of inducing a dose-related increase of plasma adenosine levels [190] . These factors together could likely ensure the integrity of endogenous cardioprotective mechanisms. At any rate, in the light of a number of large prospective studies it can be ascertained that chronic, but moderate coffee consumption (which is the main source of caffeine intake) does not increase generally the risk of coronary disease and heart failure. There might be, of course, adverse reactions associated mainly to the cardiac and neurohumoral actions of acute caffeine exposition, but these reactions might occur in a specific vulnerable population, in elderly and hypertensive patients, or when the possible adverse reactions are genetically determined [4, 191, 192] . The extremely high coffee consumption, however, carries large cardiovascular risk.
In conclusion, at present we are in a position to apply rational drug design also in the platform of adenosinergic pharmacology as there is a progressively accumulating knowledge both on the beneficial and harmful actions of endogenous and exogenous adenosine. The main goal is the development of novel structures that mimic the actions of the conventional methylxanthines as lead compounds, but their adenosine receptor subtype-specificity are higher, their water solubility are optimal, and the frequency of their adverse reactions are minimal. Therefore, the search for potent and subtype-selective adenosine receptor antagonists has been one of the most highly studied areas in medicinal chemistry [130, [193] [194] [195] [196] [197] [198] . An attractive approach of drug development could be to synthetize pharmacologically silent, clinically viable, site-and event-specific allosteric adenosine receptor antagonists with subtype selectivity, which could be an enormous challenge for both academic and industrial research groups.
